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Drugs that induce psychosis, such as D-amphetamine (AMP), and those that alleviate it, such as antipsychotics, are suggested to exert
behavioral effects via dopamine receptor D2 (D2). All antipsychotic drugs are D2 antagonists, but D2 antagonism underlies the severe and
debilitating side effects of these drugs; it is therefore important to know whether D2 is necessary for their behavioral effects. Using
D2-null mice (Drd2 / ), we first investigated whether D2 is required for AMP disruption of latent inhibition (LI). LI is a process of
learning to ignore irrelevant stimuli. Disruption of LI by AMP models impaired attention and abnormal salience allocation consequent to
dysregulated dopamine relevant to schizophrenia. AMP disruption of LI was seen in both wild-type (WT) and Drd2 / . This was in
contrast to AMP-induced locomotor hyperactivity, which was reduced in Drd2 / . AMP disruption of LI was attenuated in mice lacking
dopamine receptor D1 (Drd1 / ), suggesting that D1 may play a role in AMP disruption of LI. Further supporting this possibility, we
found that D1 antagonist SKF83566 attenuated AMP disruption of LI in WT. Remarkably, both haloperidol and clozapine attenuated
AMP disruption of LI in Drd2 / . This demonstrates that antipsychotic drugs can attenuate AMP disruption of learning to ignore
irrelevant stimuli in the absence of D2 receptors. Data suggest that D2 is not essential either for AMP to disrupt or for antipsychotic drugs
to reverse AMP disruption of learning to ignore irrelevant stimuli and further that D1 merits investigation in the mediation of AMP
disruption of these processes.
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Dopamine (DA) receptor D2 (D2) blockade is common to all
antipsychotic drugs and correlates most closely with clinical
efficacy (Howes et al, 2009; Meltzer et al, 1989; Seeman et al,
1976). Antipsychotics, however, have affinities for multiple
neurotransmitter and peptide receptors, and it is still
unknown whether D2 is essential for their behavioral effects.
There is a therapeutic imperative to establish whether
activity at D2 is obligatory for antipsychotic drug action, as
D2 blockade is also associated with extrapyramidal motor
symptoms and tardive dyskinesia, which limit compliance
(Fleischhacker et al, 1994; Kapur et al, 2000). There is
pharmacological evidence to challenge the view that
action at D2 may be solely responsible for antipsychotic
drug effects. Newer or ‘atypical’ antipsychotics such as
clozapine, while having equivalent clinical efficacy to older
‘typical’ drugs such as haloperidol, have affinity for multiple
monoamine and peptide receptors (Meltzer et al, 1989). The
therapeutic efficacy of ‘atypical’ antipsychotics can occur at
doses that produce much lower occupancy of D2 than typical
antipsychotics, although this may be explained in terms of
faster rate of dissociation from the receptor (Kapur and
Seeman, 2001). For the atypical antipsychotics clozapine and
quetiapine, no correlation is found between D2 occupancy and
reduction in clinical scores (Yilmaz et al, 2012). There is also
dissociation between the motor side effects and clinical efficacy
of antipsychotic drugs, despite both being presumed to be
mediated by D2 (Natesan et al, 2006). New putative therapies
such as metabotropic glutamate receptor agonists intended to
circumvent D2 interaction may indirectly interact with D2 (Patil
et al, 2007; Seeman and Guan, 2009). The broad pharmaco-
logical profile of antipsychotics makes it difficult to study the
functional role of individual receptors in specific behavioral
effects using drugs and no specific D2 antagonists exist. Here,
we used a null mouse approach to investigate whether D2 is
necessary for antipsychotic drugs to modify salience allocation
processes disrupted by D-amphetamine (AMP), tested using
the learning phenomenon of latent inhibition (LI).
Symptoms of schizophrenia such as hallucinations and
delusions have been suggested to reflect disruption in
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processes that allocate attention or salience to features of
the environment. This is considered to be consequent to
dysregulated DA transmission and to be remediated by
antipsychotic drugs, presumed to be via D2 blockade,
although this remains unknown (Gray et al, 1991; Kapur
et al, 2005; Howes et al, 2009). LI is widely used in animal
models of schizophrenia as an index of the mechanism
through which salience or associability (attention to and
readiness to form associations) is conferred on stimuli on
the basis of how much experience the animal has had of
them (Lubow, 2005; Weiner and Arad, 2009). LI is
demonstrated experimentally as reduced learning of a
conditioned stimulus (CS)–unconditioned stimulus (US)
association in a group pre-exposed to that stimulus without
reinforcement (pre-exposed, PE) compared with a group
without such pre-exposure (non-pre-exposed, NPE). Many,
although not all, studies show that patients with schizo-
phrenia display abnormalities in LI, which may depend on
the stage of illness (Weiner and Arad, 2009). In rats and
humans, antipsychotic drugs such as haloperidol and
clozapine potentiate low LI (Moser et al, 2000; Weiner,
2003; Weiner and Arad, 2009). On the other hand,
psychotomimetic drugs that induce psychosis, such as
AMP that inter alia increase DA release, disrupt LI.
Antipsychotic drugs attenuate this disruption in humans,
rats, and mice (Chang et al, 2007; Gray et al, 1992; Moser
et al, 2000; Weiner, 2003).
Experiments using D2-null mice (Drd2 / ) mice
suggest that D2 is essential for the behavioral and neural
effects of AMP, such as methamphetamine hyperactivity,
disruption of prepulse inhibition of the acoustic startle
response, and DA release (Boulay et al, 1999; Kelly et al,
1998; Schmitz et al, 2001). It is unknown whether D2 is
essential for disruption of LI by AMP. Direct stimulation
of D2 by the agonist apomorphine has been shown not
to disrupt LI (Lacroix et al, 2000), suggesting that D2
activation does not play a role in LI disruption, but later
reports have shown that apomorphine can disrupt LI (Melo
et al, 2009; Shao et al, 2010). This study aimed first to
investigate whether D2 is essential for AMP-induced
disruption of LI. The second aim was to investigate whether
D2 is required for antipsychotic drugs to attenuate AMPH
disruption of LI, which we found to be intact in Drd2 /
mice. The third aim was to further determine the
mechanism by which AMP disrupts LI and to investigate
whether D1 is important for AMP disruption of LI.
MATERIALS AND METHODS
Animals
The original F2 hybrid strains were generated as reported
previously (Drago et al, 1994; Kelly et al, 1997). Congenic D1
and D2 lines were established by repeatedly backcrossing
heterozygous mutants to wild-type (WT) C57BL/6 for
at least 14 generations; homozygous DA receptor D1
(Drd1 / ) and Drd2 / mice and WT (Drd1þ /þ
and Drd2þ /þ mice) littermates were then bred by
heterozygous intermatings of congenic heterozygote mu-
tants (Waddington et al, 2005). Male and female ( / and
þ /þ ) littermates were used at 10–20 weeks of age. In
experiments involving SKF83566, C57BL/6 mice were used,
which were purchased from Charles River UK (Kent, UK)
and Charles River (Wilmington, MA). Mice were housed
1–4 per cage under a 12 h light : 12 h dark cycle (lights on at
0700 hours) and constant temperature (20±2 1C) and
humidity (40–60%), with food available ad libitum. Mice
were subjected to daily water restriction periods of 23 h
throughout LI experiments, with 1 h free access to water
in their home cages after each experimental session. All
experiments were carried out in accordance with local and
national regulations on animal experimentation, and project
license authority under the Animals (Scientific Procedures)
Act, UK 1986; UK home Office Project licenses No: 40/2883
and its renewal as 40/3501.
Genotyping
This was performed by PCR using genomic DNA extracted
from ear biopsies, as described previously (Bay-Richter
et al, 2009).
Latent Inhibition
Experiments were carried out in six identical conditioning
chambers and the LI protocol was the same as that
described previously in detail (Bay-Richter et al, 2009).
For further details of the apparatus used, see Supplementary
Information. Briefly it consisted of the following:
Water restriction (Days 1–7): Mice were placed on 23-h
water restriction 7 days before and throughout the
experiment.
Pretraining (Days 8–13): Mice were placed in chambers
for 15min and the number of licks was recorded.
Pre-exposure (Day 14): Mice were placed in chambers
with no water present. They were given 60 presentations of
a 5-s 85-dB tone with an interstimulus interval of 15 s
(PE group); NPE control mice were placed in the chambers
for the same amount of time but received no tone
pre-exposures.
Conditioning (Day 15): Mice were placed in chambers
with no water present. After 2min, two tone–footshock
pairings were presented. Each tone was of 5-s duration and
followed by a 1-s 0.38-mA footshock and an intertrial
interval of 2.5min; mice remained in the chamber for
2.5min following the second shock presentation.
Re-baseline lick training (Days 16 and 17): Mice were
placed in chambers for 15min and given free access to the
water sipper to re-establish licking. Mice that did not
complete 4300 licks continuously were excluded from the
experiment and did not continue to the test day (two mice
in experiment 1 and two in experiment 2).
Test (Day 18): Mice were placed in chambers with free
access to the water sipper. The number of licks was
recorded and time taken to complete licks 80–90 (A) and
90–100 (B) recorded. After completion of 90 licks, the tone
was presented until the mouse reached lick 100 or 600 s had
elapsed. A suppression ratio (SR) was calculated according
to the formula A/(AþB) yielding a scale of 0 to 0.5.
As logarithmic transformation did not normalize data in
all experiments, SR was therefore considered the most
appropriate measure.
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This was recorded for 30min using videotracking of an
open field as described previously (Bay-Richter et al, 2009).
For further details of the apparatus used and the procedure,
see Supplementary Information.
Experimental Design and Statistics
Statistics were performed using SPSS (Versions 16 (2007)
and 18 (2009); SPSS Chicago, IL). For LI experiments,
analysis of variance (ANOVA) was used. Post hoc tests
comprised planned T-tests with Bonferroni correction for a
slippage for genotype, drug treatment group, and NPE vs PE
comparisons as appropriate. Data were collapsed across sex
as there was no significant effect of sex and no interactions
with treatment, exposure, or genotype in any experiment.
Experiments in Drd1 /mice were explicitly conducted in
females because of baseline sex differences in LI previously
identified by us; male and female Drd2 /mice and
female Drd1 /mice show comparable LI, but male
Drd1 /mice do not show LI; hence, AMP disruption
could not be evaluated in the present conditions in males
(Bay-Richter et al, 2009). Locomotor activity experiments
used split-plot ANOVA with genotype and drug treatment
group as between-group factors and 5-min time bin as
repeated-measures factor. Post hoc comparisons were
performed as described for LI experiments. The n numbers
per experiment were: 30 (9F, 21M) Drd2þ /þ and 19 (9F,
10M) Drd2 / (Figure 1a); 18 (7F, 11M) Drd2þ /þ and
12 (6M, 6F) Drd2 / (Figure 1b); 16 Drd2þ /þ (55F,
61M) and 127 (62F, 65M) Drd2 / (Figure 2); 72F
Drd1þ /þ and 57F Drd1 / (Figure 3a); 46 (23F, 23M)
Drd1þ /þ and 34 (17F, 17M) Drd1 / (Figure 3b); and
138 C57BL/6 (70F, 68M) (Figure 4). In all LI experiments,
groups did not differ in their times to complete licks 80–90
(time A) nor were there any effects of sex or interaction
between sex and other variables (all F valueso1). Owing to
the large number of experimental groups required to allow
simultaneous evaluation of clozapine and haloperidol, and
requirement for age, sex, and littermate matching, the
experiment in Figure 2 was carried out in four matched
cohort replications; there were neither significant effects of
cohort on SR nor significant interactions with exposure,
drug treatment, or genotype (all F values o1.5).
Drugs and Administration
AMP sulfate (Sigma-Aldrich, Dorset, UK) was dissolved in
sterile 0.9% (w/v) saline and a dose of 2.5mg/kg was used in
all experiments. SKF83566 (Tocris, Bristol, UK) was
dissolved in 0.9% NaCl mixed with a few drops of tartaric
acid and buffered to pH 6.5 with NaOH. Doses of 0.01 and
0.1mg/kg were used. Haloperidol and clozapine (Sigma-
Aldrich) were dissolved in 25 ml glacial acetic acid and
buffered to pH 6.5 using 0.1mM NaOH before final dilution
in sterile 0.9% saline to appropriate concentrations (0.1mg/
kg for haloperidol; 2.5mg/kg for clozapine); controls
received vehicle to the same injection volumes (10ml/kg).
Doses of AMP (2.5mg/kg, intraperitoneally) and haloper-
idol (0.1mg/kg, intraperitoneally) were based on previously
established dosage for LI in mice (Chang et al, 2007; Meyer
et al, 2004). The dose of clozapine used was lower than
published reports (Lipina et al, 2005), as significant
sedation occurred in our hands at published effective doses.
For mice receiving AMP in combination with either
haloperidol, clozapine, or SKF83566, the drug was adminis-
tered 5min before AMP, with control mice receiving a
matched number of vehicle injections. All injections were
given intraperitoneal 30min before both pre-exposure and
conditioning sessions (LI) or both habituation and testing
(locomotion). The two injection regimen is based on a
number of studies, which show that two injections of
AMPH, one before pre-exposure and one before condition-
ing, are required to disrupt LI (Weiner et al, 1988; although
see Young et al, 2005). The same regimen was then
maintained to enable direct comparison at the same doses
in locomotor activity experiments.
Figure 1 D-Amphetamine (AMP) disruption of latent inhibition (LI) is
similar in wild-type (WT) and Drd2 / (a). Vehicle-treated WT
(WT-Veh) and vehicle-treated Drd2 / (Drd2 / -Veh) mice show LI
(higher suppression ratio (SR) in pre-exposed (PE) vs non-pre-exposed
(NPE)), while D-amphetamine-treated WT (WT-AMP) and D-ampheta-
mine-treated Drd2 / (Drd2 / -AMP) mice do not. AMP locomotor
hyperactivity seen in WT is blunted in Drd2 / mice (b). *Po0.05 NPE
vs PE, same genotype and drug; þPo0.05 vs vehicle same genotype for
PE; and yPo0.05, yyPo0.001 vs vehicle same genotype and time bin.
Drd2 / , D2-null mice.
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First experiments investigated effects of AMP on LI and
locomotor activity in Drd2þ /þ and Drd2 / . Subse-
quently, effects of the typical D2 antipsychotic haloperidol
and the atypical antipsychotic clozapine on AMP disruption
of LI were investigated. To evaluate a potential role for D1 in
AMP disruption of LI, a series of experiments investigated
AMP effects on LI and locomotor activity in Drd1þ /þ and
Drd1 / and of the D1 antagonist SKF83566 on AMP
disruption of LI.
RESULTS
AMP Reduction of LI in Drd2 / Mice
AMP disrupted LI in Drd2 / mice (Figure 1a). There was
an effect of pre-exposure (F(1,41)¼ 10.89, Po0.01), treat-
ment (F(1,41)¼ 10.78, Po0.01), and a pre-exposure
treatment interaction (F(1,41)¼ 10.20, Po0.01). There was
a significant difference between AMP and vehicle in the PE
condition (T8¼ 2.749, Po0.05) and NPE vs PE (T8¼ 2.741,
Po0.05) in Drd2 / mice. There was no significant effect
of genotype nor interaction between genotype and other
factors. In Drd2þ /þ mice, there was no significant
difference between AMP and vehicle in the PE condition;
however, NPE was significantly different from PE condition,
indicating LI in the vehicle (T24¼  2.7, Po0.05) but not
the AMP group (T21¼ 0.4).
AMP Locomotor Hyperactivity in Drd2 / Mice
AMP locomotor hyperactivity was seen in WT mice, but was
blunted in Drd2 / mice using the same dose and
regimen of AMP as described for LI experiments
(Figure 1b). There was a significant effect of genotype
(F(1,22)¼ 47.23, Po0.001), drug treatment (F(1,22)¼ 33.96,
Po0.001), and a genotype drug treatment interaction
(F(1,22)¼ 8.42, Po0.01). There was a significant effect of
time bin (F(5,110)¼ 13.07, Po0.001) and an interaction
Figure 2 Haloperidol (Hal) and clozapine (Cloz) attenuate disruption of
latent inhibition (LI) by D-amphetamine (AMP) in both wild-type (WT; a)
and D2 / mice (Drd2 / ; b); *Po0.05, **Po0.01, non-pre-exposed
(NPE) vs pre-exposed (PE) same genotype and drug; þPo0.05, þ þ
Po0.01 vs AMP-PE same genotype. Drd2 / , D2-null mice.
Figure 3 D-Amphetamine (AMP) disruption of latent inhibition (LI)
(60 pre-exposed (PE)) is attenuated in Drd1 / mice (a), but locomotor
hyperactivity is not (b). *Po0.05 non-pre-exposed (NPE) vs PE same
genotype and drug; þPo0.05 vs AMP-PE same genotype; ^Po0.05 vs WT
AMP-PE; yyPo0.001 vs vehicle same genotype and time bin. Drd1 / ,
D1-null mice.
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between time bin and treatment (F(5,110)¼ 7.46, Po0.001)
but not genotype.
Antipsychotic Drug Effects on LI Reduction by AMP in
D2 / Mice
AMP disruption of LI in Drd2 / mice was attenuated by
both drugs tested, haloperidol and clozapine (Figure 2b),
demonstrating that clozapine and haloperidol do not
require the presence of D2 to attenuate AMP disruption
of LI. There were significant effects of pre-exposure
(F(1, 223)¼ 38.10, Po0.001), treatment (F(4, 223)¼ 5.01,
Po0.001), and an exposure treatment interaction (F(4,
223)¼ 2.92, Po0.05). There was no significant effect of
genotype nor interaction between genotype and other
factors (F’s o1). In WT PE groups, there was a significant
difference between AMP vs AMPþ haloperidol
(T21¼  2.68, Po0.05) and AMP vs AMPþ clozapine
(T19¼  3.43, Po0.05), and these differences were also
seen in Drd2 / mice; AMP vs AMPþ haloperidol
(T21¼  2.60, P¼ 0.01) and AMP vs AMPþ clozapine
(T19¼  3.66, Po0.005) (Figure 2b). Vehicle vs haloperidol
in PE WT group (T19¼ 2.2) was not significant. NPE
was significantly different from PE group in vehicle-
(T83¼  3.67, Po0.005), haloperidol- (T18¼  2.86,
Po0.05), AMPþ haloperidol- (T42¼  2.79, Po0.05), and
AMPþ clozapine-treated groups (T49¼  3.46, Po0.005)
but not in AMP- (T41¼  0.5) treated groups.
AMP Reduction of LI in Drd1 / Mice
We found that AMP disruption of LI is reduced in
Drd1 / mice compared with WT (Figure 3a). There
was a significant effect of drug treatment (F(1,121)¼ 4.23,
Po0.05), exposure (F(1,121)¼ 21.00, Po0.001), and geno-
type (F(1,121)¼ 4.05, Po0.05); the interaction between drug
treatment, exposure, and genotype was not significant.
There was a significant difference between AMP-WT and
AMP-Drd1 / in PE groups (T35¼ 2.24, Po0.05), sug-
gesting that AMP effect is moderated in D1 / mice.
There was a significant difference between NPE and PE
groups in vehicle- (T31¼ 2.97, Po0.05) and AMP-treated
Drd1 / (T28¼  2.5, Po0.05), suggesting LI in these
groups but not in AMP-treated Drd1þ /þ or vehicle-
treated Drd1 / groups.
AMP Locomotor Hyperactivity in Drd1 / Mice
AMP locomotor hyperactivity was maintained in both WT
and Drd1 / mice (Figure 3b). There was a significant
effect of drug treatment (F(1, 76)¼ 55.50, Po0.001) but no
effect of genotype. There was also a significant effect of time
bin (F(5,380)¼ 13.4, Po0.001) and an interaction between
time bin and drug treatment (F(5,380)¼ 9.44, Po0.001.
D1 Antagonist SKF83566 Effect on AMP Reduction
of LI in C57/BL/6 Mice
Figure 4 shows that pretreatment with SKF83566 at
0.1mg/kg but not 0.01mg/kg prevented AMP disruption
of LI. These data suggest that D1 antagonism can be
sufficient to prevent AMP disruption of LI. There was a
significant effect of exposure (F(1, 116)¼ 21.38, Po0.001)
and drug treatment (F(5, 116)¼ 2.65, Po0.05) and a drug
treatment exposure interaction (F(5, 116)¼ 2.33, Po0.05).
There was a significant difference between PE groups
AMPþ SKF 0.1mg/kg and AMP (T21¼ 2.6, Po0.05). There
was a significant difference between NPE and PE conditions
in vehicle (T21¼  2.37, Po0.05), AMPþ SKF 0.1mg/kg
(T21¼  2.4, Po0.05), and SKF 0.01mg/kg (T22¼  2.7,
Po0.01) groups but not in SKF 0.1mg/kg (T21¼ 1.9) or
AMPH-treated group (T’s o0.5).
DISCUSSION
These data show first that AMP disrupts LI in mice lacking
D2 receptors, demonstrating that AMP can influence
behavior in the absence of D2. This effect of AMP may be
specific to processes involved in learning to ignore
irrelevant stimuli, as locomotor hyperactivity induced by
the same regimen of AMP was blunted in mice lacking D2
receptors. Second, it was found that the D2 receptor is not
essential for antipsychotic drugs haloperidol and clozapine
to attenuate LI disruption induced by AMP. This has
important therapeutic implications as it suggests that it is
possible to modulate impaired ability to ignore irrelevant
stimuli induced by a hyperdopaminergic state without
interaction with D2. Third, AMP disruption of LI was
blunted in the absence of D1, suggesting that its effects to
disrupt LI may require D1. Hyperactivity induced by AMP
at the same dose was not affected in the absence of D1,
suggesting dissociation between the effects of AMP on LI
and on locomotor activity. AMP disruption of LI was
attenuated by the D1 antagonist SKF83566, suggesting
further that D1 merits further investigation in the mediation
of AMP disruption of LI.
Understanding the biological basis of the cognitive effects
of AMP and how it affects the selection of information are
Figure 4 D-Amphetamine (AMP) reduction of latent inhibition (LI) in
wild-type (WT) mice is attenuated by pretreatment with SKF83566 at
0.1mg/kg but not 0.01mg/kg. *Po0.05 non-pre-exposed (NPE) vs pre-
exposed (PE) same drug; þPo0.05, þ þPo0.01 vs AMP-PE.
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important for the understanding of both its abuse potential
and psychotomimetic effects. AMP produces a wide variety
of behavioral effects, including psychosis, locomotor
hyperactivity, stereotypy, self-administration, and disrup-
tion of sensori motor gating in a variety of species (Angrist
et al, 1980; Cole, 1978; Hutchison and Swift, 1999; Mansbach
et al, 1988; Marriott, 1968; Ralph-Williams et al, 2002). A
consistent feature of these behavioral effects of AMP is that
they are prevented by antipsychotic drugs that block D2,
leading to their application as animal models relevant to
schizophrenia. Studies in null mice also suggest that D2
plays a crucial role in mediating AMP behavioral effects
(Kelly et al, 2008; Ralph et al, 1999). We show that D2 is not
essential for AMP to exert its disruptive effect on LI, yet
hyperactivity induced by the same dose and regimen of
AMP is reduced in the absence of D2. Reduced locomotor
activity in Drd2 / mice replicates previous findings
using mixed background strains (Kelly et al, 1998). Data
suggest that acute stimulatory effects of AMP using this
dose and treatment regimen may require D2. Statistical
interaction between genotype and treatment suggests that
this is distinguishable from baseline reduction in activity in
Drd2 / mice. This finding is consistent with evidence
showing reduced acute stimulatory effects of methamphe-
tamine in Drd2 / mice (Kelly et al, 2008).
Preserved AMP disruption of LI in Drd2 / is
consistent with pharmacological studies indicating no effect
of direct D2 agonist apomorphine on LI in rats (eg Broersen
et al, 1999, Lacroix et al, 2000). It is notable that in some
cases where LI has been disrupted by apomorphine, it is
NPE disruption that produced the loss of LI, making effects
on LI per se difficult to interpret (eg Melo et al, 2009, Shao
et al, 2010).
As AMP acts via presynaptic mechanisms to increase the
release of a number of neurotransmitters, including
noradrenaline and serotonin, as well as DA, it is possible
that its primary DAergic mechanism is devolved to a
different mechanism in compensation for developmental
absence of D2 in Drd2 / mice. There is electrophysio-
logical evidence that firing of DA neurons induced by AMP
in the ventral tegmental area switches to a noradrenergic
mechanism in the pharmacological absence of D2, that is, in
the presence of a D2 antagonist (Cohen and Lipinski, 1986;
Shi et al, 2000). Most antipsychotic drugs have affinity at
the noradrenaline a1 receptor (Cohen and Lipinski, 1986)
as well as D2 and other DA receptor subtypes, making
action through noradrenergic modulation one possible
mechanism.
Remarkably, we found that AMP disruption of LI is
attenuated by haloperidol and clozapine and does not
require the presence of D2. This surprising outcome
suggests that attenuation of AMP-induced abnormal
salience allocation by antipsychotic drugs can occur in the
absence of D2. There are a number of possible candidate
biological mechanisms. Drugs such as 5-HT2A receptor
antagonists have been shown to reverse AMP disruption of
LI in rats (Weiner and Arad, 2009); 5-HT2A antagonism is a
putative feature of ‘atypical’ antipsychotics and polymorph-
isms in 5-HT2A genes have been reported in schizophrenia
(Maier et al, 2008; Miyamoto et al, 2005). It is worth noting
that 5-HT2A receptors modulate activated but not basal
mesolimbic DA function (Schmidt and Fadayel, 1996;
Schmidt et al, 1995). However, while clozapine has
significant affinity for 5-HT2A receptors, haloperidol does
not, particularly at the dose used in this study. Interaction
with the cholinergic system is also a possible mechanism.
Muscarinic receptor M4 agonists have been suggested to
have antipsychotic potential (Shekhar et al, 2008; Dencker
et al, 2011) and have been shown to reverse AMP disruption
of LI (Barak and Weiner, 2011). Abnormal glutamatergic
neurotransmission, particularly at N-methyl-D-aspartate
(NMDA)-type glutamate receptors, has also been implicated
in schizophrenia (Olney et al, 1999). NMDA receptors are
regulated by the amino-acid glycine and drugs that interact
with transporters for glycine (GlyT1) may have antipsycho-
tic potential (Javitt, 2012). The GlyT1inhibitor SSR103800
has furthermore been shown to reduce AMP disruption
of LI (Black et al, 2009). The mechanism of the
D2-independent action of these drugs has yet to be
identified; however, AMP-disrupted LI in Drd2 / mice
may be of use as a novel model system to identify D2-
independent effects of these drugs. Their identification
could suggest neural strategies to remediate hyperdopami-
nergia-related disruption in a behaviorally specific manner
without interaction with D2.
One interpretation of these findings is that AMP effects in
Drd2 / mice differ from AMP effects in APD-treated
mice, broadly suggesting dissociation between pharmaco-
logical and genetic manipulations of D2 in the presence of
AMP. We have shown previously that in the absence of
AMP both potentiate low levels of LI and effects on
locomotor activity are consistent, indicating that this
dissociation is not a general phenomenon or even specific
for LI (Moser et al, 2000; Bay-Richter et al, 2009). One
possible explanation is that if AMP interacts with D1 to
disrupt LI as later experiments suggest, then the D1
antagonist action of APD would reverse AMP disruption
of LI by pharmacological antagonism. This would not be
seen in Drd2 / ; hence, a dissociation would be found.
It is also possible that Drd2 / mice differ in metabolism
or neural activity consequent to developmental absence of
Drd2 and this becomes unmasked in the presence of AMP.
We cannot determine from this study whether that is the
case or not, but this possibility does not alter the conclusion
from the study that D2 is not essential for AMP disruption
of LI.
Our findings indicate an attenuation of AMP disruption
of LI in female Drd1 / mice. This is consistent with the
observation that the diverse pharmacological actions of
psychotomimetic drugs, such as AMP, LSD, and PCP,
include effects on D1-mediated function (Watts et al, 1995).
Supporting a role for Drd1 / , we showed that SKF83566
attenuated the effects of AMP on LI. In contrast, we show
that AMP effects on locomotor activity are not reduced in
Drd1 / mice. AMP hyperlocomotor activity has pre-
viously been shown to be blunted in Drd1 / mice on
mixed background strains following acute and repeated
administration (Xu et al, 2000; Crawford et al, 1997).
We cannot determine whether this difference is due to
background strain difference, dose, or dosing regimen of
AMP. However, intact locomotor stimulation by AMP in
Drd1 / mice is clearly dissociable from both attenuated
locomotor stimulation seen in their Drd2 / counterparts
and attenuated disruption of LI in Drd1 / female mice
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using the same dose and regimen of AMP. There is a
possibility that this finding is sex-specific as male
Drd1 / could not be evaluated in these conditions, as
they do not show robust LI. Recently, it has been shown in
male rat studies that the D1 antagonist SCH23390 can
reverse AMP effects on LI (Nelson et al, 2012), suggesting
that these effects may not be specific to mice or females.
Previous rat studies have shown that LI disruption by
nicotine is also reversed by D1 antagonists. Nicotine (like
AMP) is thought to disrupt LI via mesolimbic DA release
and is reversed by antipsychotic drugs (Joseph et al, 1993;
Moran et al, 1996; Young et al, 2005). Taken together with
the present data, we suggest that the role of D1 in drug
effects to disrupt and potentially improve salience allocation
merits further investigation. It has been suggested that D1
antagonism may be important for the behavioral effects of
antipsychotics and may be secondary to D2 antagonism
(Josselyn et al, 1997; Miller, 1990, 2009). A potential role for
D1 in AMP disruption of LI is consistent with studies in rats
implicating D1 in overshadowing, a related measure of
salience allocation, other behavioral effects of AMP in other
species, as well as a more general role for midbrain D1 in
attentional accuracy (Liu et al, 2010, 2011; O’Tuathaigh and
Moran, 2002; Zelikowsky and Fanselow, 2010).
Translation of the outcome of experiments using animal
model systems to human psychosis and its treatment must
include the caveat of species and environmental differences
from the human condition. In these studies, mice were
water restricted; there is a possibility that this may be
important for demonstration of the effects we have shown.
In rats, it has been shown that drinking in water-restricted
rats can increase midbrain DA release (Young et al, 1992). It
is possible that cross-sensitization may have occurred
between effects of water restriction and AMP effects on
DA release in key brain regions such as the nucleus
accumbens. Sensitization of the locomotor response
induced by AMP has been shown specifically to involve
D1 (Vezina, 1996); further experiments would be required to
test this possibility.
CONCLUSION
We have demonstrated the principle that AMP, clozapine,
and haloperidol can exert behavioral effects in the absence
of D2 in mice. These D2-independent effects may be
behaviorally specific to the process of learning to ignore
irrelevant stimuli and allocating salience appropriately
as measured in LI. D1 merits further investigation in
the mediation of these effects. Identification of this
D2-independent mechanism may constitute a novel
behavior-driven approach to identify existing and candidate
antipsychotic drug actions that are behaviorally specific and
independent of D2.
ACKNOWLEDGEMENTS
This work was supported by The Wellcome Trust, UK
(WT0845921Z) and Science Foundation Ireland Principal
Investigator Grant (07/IN.1/B960). CBR and NM were
funded by studentships from the School of Psychology,
University of Nottingham, UK. DRD1 / mice were bred
with the kind permission of Dr John Drago (University of
Melbourne, Melbourne, VIC, Australia); D2 / mice were
bred with the kind permission of Dr Malcolm Low (Oregon
Health and Science University, Portland, OR). CBR is
now at the Department of Psychoneuroimmunology,
Section for Psychiatry Department of Clinical Sciences,
Lund, Sweden. MJO’C is now at Cerca Insights Sdn Bhd,
Northern Corridor Technology Development Center
(NTDC), Penang, Malaysia.
DISCLOSURE
The authors declare no conflict of interest.
REFERENCES
Angrist B, Rotrosen J, Gershon S (1980). Responses to apomor-
phine, amphetamine, and neuroleptics in schizophrenic subjects.
Psychopharmacology 67: 31–38.
Barak S, Weiner I (2011). The M/M4 preferring agonist xanomeline
reverses amphetamine-, MK801- and scopolamine-induced
abnormalities of latent inhibition: putative efficacy against
positive, negative and cognitive symptoms in schizophrenia..
Int J Neuropsychopharmacol 14: 1233–1246.
Bay-Richter C, O’Tuathaigh CMP, O’Sullivan G, Heery DM,
Waddington JL, Moran PM (2009). Enhanced latent inhibition
in dopamine receptor-deficient mice is sex-specific for the D-1
but not D-2 receptor subtype: implications for antipsychotic
drug action. Int J Neuropsychopharmacol 12: 403–414.
Black M, Varty G, Aarad M, Barak S, DeLevie A, Boulay D et al
(2009). Procognitive and antipsychotic efficacy of glycine
transport 1 inhibitors (GlyT1) in acute and neurodevelopmental
models of schizophrenia: latent inhibition studies in the rat.
Psychopharmacology 202: 385–396.
Boulay D, Depoortere R, Perrault G, Borrelli E, Sanger DJ (1999).
Dopamine D-2 receptor knock-out mice are insensitive to the
hypolocomotor and hypothermic effects of dopamine D-2/D-3
receptor agonists. Neuropharmacology 38: 1389–1396.
Broersen LM, Feldon J, Weiner I (1999). Dissociative effects of
apomorphine infusions into the medial prefrontal cortex of rats
on latent inhibition, prepulse inhibition and amphetamine-
induced locomotion. Neuroscience 94: 39–46.
Chang T, Meyer U, Feldon J, Yee BK (2007). Disruption of the US
pre-exposure effect and latent inhibition in two-way active
avoidance by systemic amphetamine in C57BL/6 mice. Psycho-
pharmacology 191: 211–221.
Cohen BM, Lipinski JF (1986). In vivo potencies of antipsychotic-
drugs in blocking alpha-1 noradrenergic and dopamine D2
receptors—implications for drug mechanisms of action. Life Sci
39: 2571–2580.
Cole SO (1978). Brain mechanisms of amphetamine-induced
anorexia, locomotion, and stereotypy—review. Neurosci
Biobehav Rev 2: 89–100.
Crawford CA, Drago J, Watson JB, Levine MS (1997). Effects of
repeated amphetamine treatment on the locomotor activity of
the dopamine D1A-deficient mouse. Neuroreport 8: 2523–2527.
Dencker B, Wortwein G, Weikop P, Jeon J, Thomsen M, Sager TN
et al (2011). Involvement of a subpopulation of Neuronal M4
Muscarinic Acetylcholine receptors in the antipsychotic effect of
the Muscarinic receptor Agonist Xanomeline. J Neurosci 31:
5905–5908.
Drago J, Gerfen CR, Lachowicz JE, Steiner H, Hollon TR, Love PE
et al (1994). Altered striatal function in a mutant mouse
lacking D-1a dopamine-receptors. Proc Natl Acad Sci US A 91:
12564–12568.
Antipsychotics and amphetamine in D2-null mice
C Bay-Richter et al
1518
Neuropsychopharmacology
Fleischhacker WW, Meise U, Gunther V, Kurz M (1994).
Compliance with antipsychotic drug-treatment—influence of
side-effects. Acta Psychiatr Scand 89: 11–15.
Gray JA, Feldon J, Rawlins JNP, Smith AD, Hemsley DR (1991).
The neuropsychology of schizophrenia. Behav Brain Sci 14: 1–19.
Gray NS, Hemsley DR, Gray JA (1992). Abolition of latent
inhibition in acute, but not chronic, schizophrenics. Neurol
Psychiatry Brain Res 1: 83–89.
Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S
(2009). Mechanisms underlying psychosis and antipsychotic
treatment response in schizophrenia: insights from PET and
SPECT imaging. Curr Pharm Design 15: 2550–2559.
Hutchison KE, Swift R (1999). Effect of d-amphetamine on
prepulse inhibition of the startle reflex in humans. Psychophar-
macology 143: 394–400.
Javitt DC (2012). Glycine transport inhibitors in the treatment of
schizophrenia. Handbook Exp Pharmacol 213: 367–399.
Joseph MH, Peters SL, Gray JA (1993). Nicotine blocks latent
inhibition in rats—evidence for a critical role of increased
functional-activity of dopamine in the mesolimbic system at
conditioning rather than preexposure. Psychopharmacology 110:
187–192.
Josselyn SA, Miller R, Beninger RJ (1997). Behavioral effects of
clozapine and dopamine receptor subtypes. Neurosci Biobehav
Rev 21: 531–558.
Kapur S, Mizrahi R, Li M (2005). From dopamine to salience to
psychosis - linking biology, pharmacology and phenomenology
of psychosis. Schizophr Res 79: 59–68.
Kapur S, Seeman P (2001). Does fast dissociation from the
dopamine D-2 receptor explain the action of atypical anti-
psychotics?: a new hypothesis. Am J Psychiatry 158: 360–369.
Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000).
Relationship between dopamine D-2 occupancy, clinical
response, and side effects: a double-blind PET study of
first-episode schizophrenia. Am J Psychiatry 157: 514–520.
Kelly MA, LowMJ, Rubinstein M, Phillips TJ (2008). Role of dopamine
D1-like receptors in methamphetamine locomotor responses of D2
receptor knockout mice. Genes Brain Behav 7: 568–577.
Kelly MA, Rubinstein M, Asa SL, Zhang G, Saez C, Bunzow JR et al
(1997). Pituitary lactotroph hyperplasia and chronic hyperpro-
lactinemia in dopamine D2 receptor-deficient mice. Neuron 19:
103–113.
Kelly MA, Rubinstein M, Phillips TJ, Lessov CN, Burkhart-Kasch S,
Zhang G et al (1998). Locomotor activity in D2 dopamine
receptor-deficient mice is determined by gene dosage, genetic
background, and developmental adaptations. J Neurosci 18:
3470–3479.
Killcross AS, Dickinson A, Robbins TW (1994). Amphetamine-
induced disruptions of latent inhibition are reinforcer
mediated—implications for animal-models of schizophrenic
attentional dysfunction. Psychopharmacology 115: 185–195.
Lacroix L, Broersen LM, Feldon J, Weiner I (2000). Effects of local
infusions of dopaminergic drugs into the medial prefrontal
cortex of rats on latent inhibition, prepulse inhibition and
amphetamine induced activity. Behav Brain Res 107: 111–121.
Lipina T, Labrie V, Weiner I, Roder J (2005). Modulators of the
glycine site on NMDA receptors, D-serine and ALX 5407, display
similar beneficial effects to clozapine in mouse models of
schizophrenia. Psychopharmacology 179: 54–67.
Liu Y, Aragona BJ, Young KA, Dietz DM, Kabbaj M, Mazei-
Robison M et al (2010). Nucleus accumbens dopamine mediates
amphetamine-induced impairment of social bonding in a
monogamous rodent species. Proc Natl Acad Sci USA 107:
1217–1222.
Liu Y, Young KA, Curtis JT, Aragona BJ, Wang ZX (2011). Social
bonding decreases the rewarding properties of amphetamine
through a dopamine D1 receptor-mediated mechanism.
J Neurosci 31: 7960–7966.
Lubow RE (2005). Construct validity of the animal latent inhibition
model of selective attention deficits in schizophrenia. Schizophr
Bull 31: 139–153.
Maier W, Mossner R, Quednow BB, Wagner M, Hurlemann R
(2008). From genes to psychoses and back: the role of the 5HT2
alpha-receptor and prepulse inhibition in schizophrenia. Eur
Archiv Psychiatry Clin Neurosci 258: 40–43.
Mansbach RS, Geyer MA, Braff DL (1988). Dopaminergic
stimulation disrupts sensorimotor gating in the rat. Psychophar-
macology 94: 507–514.
Marriott AS (1968). Effects of amphetamine caffeine and
methylphenidate on locomotor activity of rats in an unfamiliar
environment. Int J Neuropharmacol 7: 487–48.
Melo LL, Pereira EC, Pagini CH, Coimbra NC, Branda˜o ML, Ferrari
EA (2009). Effects of microinjections of apomorphine and
haloperidol into the inferior colliculus on the latent inhibition of
the conditioned emotional response. Exp Neurol 216: 16–21.
Meltzer HY, Matsubara S, Lee JC (1989). Classification of typical
and atypical antipsychotic-drugs on the basis of dopamine D-1,
D-2 and serotonin2 Pki values. J Pharmacol Exp Therap 251:
238–246.
Meyer U, Chang DLT, Feldon J, Yee BK (2004). Expression of the
CS- and US-pre-exposure effects in the conditioned taste
aversion paradigm and their abolition following systemic
amphetamine treatment in C57BL6/J mice. Neuropsychopharma-
cology 29: 2140–2148.
Miller R (2009). Mechanisms of action of antipsychotic drugs of
different classes, refractoriness to therapeutic effects of classical
neuroleptics, and individual variation in sensitivity to their
actions: PART II. Curr Neuropharmacol 7: 315–330.
Miller R, Wickens JR, Beninger RJ (1990). Dopamine D-1-receptor
and D-2-receptor in relation to reward and performance—a case
for the D-1-receptor as a primary site of therapeutic action of
neuroleptic drugs. Progr Neurobiol 34: 143–183.
Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005).
Treatments for schizophrenia: a critical review of pharmacology
and mechanisms of action of antipsychotic drugs. Mol Psychiatr
10: 79–104.
Moran PM, Fischer TR, Hitchcock JM, Moser PC (1996). Effects of
clozapine on latent inhibition in the rat. Behav Pharmacol 7: 42–48.
Moser PC, Hitchcock JM, Lister S, Moran PM (2000). The
pharmacology of latent inhibition as an animal model of
schizophrenia. Brain Res Rev 33: 275–307.
Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S (2006).
Dissociation between in vivo occupancy and functional antag-
onism of dopamine D-2 receptors: comparing aripiprazole to
other antipsychotics in animal models. Neuropsychopharmacol-
ogy 31: 1854–1863.
Nelson AJ, Thur KE, Cassaday HJ (2012). Dopamine D1 receptor
involvement in latent inhibition and overshadowing. Int J
Neuropharmacol 15: 1513–1523.
Olney JW, Newcomer JW, Farber NB (1999). NMDA receptor
hypofunction model of schizophrenia. J Psychiatric Res 33:
523–533.
O’Tuathaigh CMP, Moran PM (2002). Evidence for dopamine D-1
receptor involvement in the stimulus selection task: over-
shadowing in the rat. Psychopharmacology 162: 225–231.
Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV
et al (2007). Activation of mGlu2/3 receptors as a new approach
to treat schizophrenia: a randomized phase 2 clinical trial. Nat
Med 13: 1102–1107.
Ralph RJ, Varty GB, Kelly MA, Wang YM, Caron MG, Rubinstein
M et al (1999). The dopamine D-2, but not D-3 or D-4,
receptor subtype is essential for the disruption of prepulse
inhibition produced by amphetamine in mice. J Neurosci 19:
4627–4633.
Ralph-Williams RJ, Lehmann-Masten V, Otero-Corchon V, Low
MJ, Geyer MA (2002). Differential effects of direct and indirect
Antipsychotics and amphetamine in D2-null mice
C Bay-Richter et al
1519
Neuropsychopharmacology
dopamine agonists on prepulse inhibition: a study in D1 and D2
receptor knock-out mice. J Neurosci 22: 9604–9611.
Schmidt CJ, Fadayel GM (1996). Regional effects of MK-801 on
dopamine release: effects of competitive NMDA or 5-HT2A
receptor blockade. J Pharmacol Exp Therap 277: 1541–1549.
Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG
(1995). The role of 5-Ht2a receptors in antipsychotic activity.
Life Sci 56: 2209–2222.
Schmitz Y, Lee CJ, Schmauss C, Gonon F, Sulzer D (2001).
Amphetamine distorts stimulation-dependent dopamine over-
flow: effects on D2 autoreceptors, transporters, and synaptic
vesicle stores. J Neurosci 21: 5916–5924.
Seeman P, Guan HC (2009). Glutamate agonist LY404,039 for
treating schizophrenia has affinity for the dopamine D2(high)
receptor. Synapse 63: 935–939.
Seeman P, Lee T, Chauwong M, Wong K (1976). Antipsychotic
drug doses and neuroleptic-dopamine receptors. Nature 261:
717–719.
Shao F, Han X, Li N, Wang W (2010). Adolescent chronic
apomorphine treatment impairs latent inhibition and reduces
prefrontal cortex mGluR5 receptor expression in adult rats. Eur J
Pharmacol 649: 202–205.
Shekhar A, Potter WZ, Lightfoot J, Lienmemann J, Dube S,
Mallinckrodt C et al (2008). Selective muscarinic receptor
agonist xanomeline as a novel treatment approach for schizo-
phrenia. Am J Psychiatry 165: 1033–1039.
Shi WX, Pun CL, Zhang XX, Jones MD, Bunney BS (2000). Dual
effects of D-amphetamine on dopamine neurons mediated by
dopamine and nondopamine receptors. J Neurosci 20: 3504–3511.
Vezina P (1996). D1 dopamine receptor activation is necessary for
the induction of sensitization by amphetamine in the ventral
tegmental area. J Neurosci 16: 2411–2420.
Waddington JL, O’Tuathaigh C, O’Sullivan G, Tomiyama K,
Koshikawa N, Croke DT (2005). Phenotypic studies on
dopamine receptor subtype and associated signal transduction
mutants: insights and challenges from 10 years at the
psychopharmacology-molecular biology interface. Psychophar-
macology 181: 611–638.
Watts VJ, Lawler CP, Fox DR, Neve KA, Nichols DE, Mailman RB
(1995). Lsd and structural analogs—pharmacological evaluation
at D-1 dopamine-receptors. Psychopharmacology 118: 401–409.
Weiner I (2003). The ‘two-headed’ latent inhibition model of
schizophrenia: modeling positive and negative symptoms and
their treatment. Psychopharmacology 169: 257–297.
Weiner I, Arad M (2009). Using the pharmacology of latent
inhibition to model domains of pathology in schizophrenia and
their treatment. Behav Brain Res 204: 369–386.
Weiner I, Bernasconi E, Broersen LM, Feldon J (1997). Amphe-
tamine-induced disruption of latent inhibition depends on the
nature of the stimulus. Behav Pharmacol 8: 442–457.
Weiner I, Lubow RE, Feldon J (1988). Disruption of latent
inhibition by acute administration of low doses of amphetamine.
Pharmacol Biochem 30: 871–878.
Xu M, Guo YH, Vorhees CV, Zhang JH (2000). Behavioral
responses to cocaine and amphetamine administration in mice
lacking the dopamine D1 receptor. Brain Res 852: 198–207.
Yilmaz Z, Zai CC, Hwang R, Mann S, Arenovich T, Remington G
et al (2012). Antipsychotics, dopamine D2 receptor occupancy
and clinical improvement in schizophrenia: a meta-analysis.
Schizophr Res 140: 214–220.
Young AMJ, Joseph MH, Gray JA (1992). Increased dopamine
release in vivo in nucleus accumbens and caudate nucleus of the
rat during drinking: a microdialysis study. Neuroscience 48:
871–876.
Young AMJ, Moran PM, Joseph MH (2005). The role of dopamine
in conditioning and latent inhibition: What, when, where and
how? Neurosci Biobehav Rev 29: 963–976.
Zelikowsky M, Fanselow MS (2010). Opioid regulation of pavlovian
overshadowing in fear conditioning. Behav Neurosci 124:
510–519.
This work is licensed under a Creative Commons
Attribution-NonCommercial-ShareAlike 3.0 Un-
ported License. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-sa/3.0/
Supplementary Information accompanies the paper on the Neuropsychopharmacology website (http://www.nature.com/npp)
Antipsychotics and amphetamine in D2-null mice
C Bay-Richter et al
1520
Neuropsychopharmacology
